David T. Rubin to Glucocorticoids
This is a "connection" page, showing publications David T. Rubin has written about Glucocorticoids.
Connection Strength
1.230
-
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17.
Score: 0.451
-
Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
Score: 0.373
-
Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician. Am J Gastroenterol. 2020 10; 115(10):1566-1569.
Score: 0.160
-
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
Score: 0.120
-
Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
Score: 0.102
-
Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014 Jan; 20(1):14-20.
Score: 0.025